Literature DB >> 3099603

A comparison of alfentanil pharmacokinetics in children and adults.

C Meistelman, C Saint-Maurice, M Lepaul, J C Levron, J P Loose, K Mac Gee.   

Abstract

The pharmacokinetics of alfentanil have been studied in eight children aged between 4 and 8 yr and five adults during general anesthesia. All patients were given 20 micrograms/kg alfentanil as an intravenous bolus injection. Plasma concentrations were measured at intervals up to 6 h by radioimmunoassay. Plasma protein binding was measured by equilibrium dialysis using tritiated alfentanil. The optimal pharmacokinetic model for alfentanil was an open two-compartment model. Total apparent volume of distribution (Vdss) was 457 +/- 160 ml/kg in adults and 163 +/- 110 ml/kg in children (P less than 0.01). When recalculated by surface area Vdss was still decreased in children (P less than 0.01). Plasma clearance (Cl) was similar in the two groups. Terminal elimination half-life was significantly shorter in children (40 +/- 9 min) than in adults (97 +/- 22 min; P less than 0.01). The shorter elimination half-life could be due to the smaller total apparent volume of distribution in children. Plasma protein binding was comparable between children and adults and could not explain the smaller volume of distribution in children. It is suggested that the smaller volume of distribution of alfentanil in children is a result of the decreased percentage of fat tissue in children.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3099603     DOI: 10.1097/00000542-198701000-00003

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  15 in total

1.  Sex, age and alfentanil pharmacokinetics.

Authors:  A Rubio; C Cox
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

2.  A mechanistic approach for the scaling of clearance in children.

Authors:  Andrea N Edginton; Walter Schmitt; Barbara Voith; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

4.  Aging and alfentanil disposition in healthy volunteers and surgical patients.

Authors:  D S Sitar; P C Duke; J L Benthuysen; T J Sanford; N T Smith
Journal:  Can J Anaesth       Date:  1989-03       Impact factor: 5.063

Review 5.  Clinical pharmacokinetics of sedatives in neonates.

Authors:  E Jacqz-Aigrain; P Burtin
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.

Authors:  J Scholz; M Steinfath; M Schulz
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

7.  Safety and efficacy of alfentanil and halothane in paediatric surgical patients.

Authors:  J J Mulroy; P J Davis; D B Rymer; K A Chaitoff; J R Boston; H R Westman; D R Cook
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

Review 8.  Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children.

Authors:  K T Olkkola; K Hamunen; E L Maunuksela
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

9.  Alfentanil pharmacokinetics in preterm infants.

Authors:  N Marlow; A M Weindling; A Van Peer; J Heykants
Journal:  Arch Dis Child       Date:  1990-04       Impact factor: 3.791

10.  Alfentanil infusion for sedation in infants and small children during cardiac catheterization.

Authors:  P Rautiainen
Journal:  Can J Anaesth       Date:  1991-11       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.